ProBiotix Health

Listed UK biopharmaceutical company founded in 2012, specializing in developing and supplying scientifically validated probiotic-based microbiome solutions for cardiovascular and cardiometabolic health. Lead strain LPLDL® (Lactobacillus plantarum) demonstrated in independent clinical trials: total cholesterol reduction 36%, LDL 28%, apolipoprotein B 28%. CholBiome range covers cholesterol, hypertension and vascular health.